Capricor Therapeutics (CAPR) Reiterated at Overweight by Cantor Fitzgerald
Tweet Send to a Friend
Cantor Fitzgerald analyst Kristen Kluska reiterated an Overweight rating and $62.00 price target on Capricor Therapeutics (NASDAQ: CAPR).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
